PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
Kim Linton,
Jeanette Doorduijn,
Dima El-Sharkawi,
Rogier Mous,
Francesco Forconi,
David Lewis,
Mary Gleeson,
John Riches,
Pam Mckay,
Wendy Stevens,
Sarah G Injac,
Graham P Collins
Affiliations
Kim Linton
1 Manchester Cancer Research Centre, Division of Cancer Sciences, Manchester, United Kingdom
Jeanette Doorduijn
2 Erasmus MC Cancer Institute, on behalf of the Lunenburg Lymphoma Phase I/II Consortium – HOVON/LLPC, Rotterdam, The Netherlands
Dima El-Sharkawi
3 Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
Rogier Mous
4 UMC Utrecht Cancer Center, University Medical Center Utrecht, on behalf of the Lunenburg Lymphoma Phase I/II Consortium – HOVON/LLPC, Utrecht, The Netherlands
Francesco Forconi
5 University Hospital Southampton NHS Trust, Southampton, United Kingdom
David Lewis
6 Derriford Hospital, Plymouth, United Kingdom
Mary Gleeson
7 Sarah Cannon Research Institute, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
John Riches
8 Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Pam Mckay
9 Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
Wendy Stevens
10 Radboud University Medical Center, on behalf of the Lunenburg Lymphoma Phase I/II Consortium – HOVON/LLPC, Nijmegen, The Netherlands
Sarah G Injac
11 Nurix Therapeutics, Inc., San Francisco, United States
Graham P Collins
12 Oxford University Hospitals Foundation NHS Trust,, Oxford, United Kingdom
